Article info
PDFTherapeutics
Randomised controlled trial
Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride
- Correspondence to
: Dr Denise L Campbell-Scherer
Department of Family Medicine, University of Alberta, 205 College Plaza, 8215 112 St NW, Edmonton, Alberta, Canada AB T6G 2C8; denise.campbell-scherer{at}ualberta.ca
Citation
Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride
Publication history
- First published March 8, 2013.
Online issue publication
October 25, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions